ReviewDiscover oncology2026
Mechanisms and therapeutic implications of metabolic heterogeneity and histone lactylation in clear cell renal cell carcinoma.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC) is characterized by metabolic reprogramming and epigenetic dysregulation, primarily attributable to the loss of the Von Hippel-Lindau(VHL) gene and the resulting stabilization of HIF.Its metabolism is predominantly driven by the Warburg effect. However, metabolic patterns vary both across different tumors and within individual tumors.Histone lactylation is a recently discovered epigenetic mark linking glycolysis-derived lactate to gene expression.Lactate accumulation drives histone lactylation, thereby regulating the expression of genes involved in tumor progression and other malignant phenotypes.The interplay between metabolic diversity and histone modifications shapes distinct tumor phenotypes and their microenvironments.Finally, emerging therapies-including HIF-2α inhibitors, metabolic enzyme inhibitors, and epigenetic regulators-are introduced along with their potential use in combination with immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.